跳至主要内容
临床试验/NCT06424210
NCT06424210已完成不适用

The Role of Surgery for Esophageal Cancer With Metastatic Disease (M1)

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 163 人开始时间: 2023年2月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
163
试验地点
1
主要终点
Overall survival and progression-free survival

研究概览

简要总结

Treatment of stage IV esophageal cancer is traditionally palliative, but treatment response is usually poor. The role of surgery in the treatment of advanced esophageal cancer remains controversial. We sought to determine whether surgical treatment followed by neoadjuvant chemoradiation therapy might provide survival benefits for these patients.

A retrospective review of esophageal cancer patients with M1 disease treated at National Taiwan University Hospital was performed from April 2002 to June 2021. Patient demographics and cancer staging, treatment, and disease recurrence, and time of follow up were included for analysis. Univariate and multivariate analysis was performed for overall survival and progression-free survival analysis. Propensity score matching based on patient age and tumor staging characteristics was also performed for analysis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stage IV Esophageal Cancer patients
  • Patients were treated with chemoradiation therapy (CCRT)

排除标准

  • Not Stage IV Esophageal Cancer patients
  • Patients were not treated with chemoradiation therapy (CCRT)

结局指标

主要结局

Overall survival and progression-free survival

时间窗: 5 years

Overall survival (OS) and progression-free survival (PFS) curves of patients with or without esophagectomy in the entire study cohort of stage IV esophageal cancer with distant metastasis.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验